2nd Nov 2026 21:30
DBV Technologies to Participate in Upcoming November Investor ConferencesChâtillon, France, November 2, 2026
DBV Technologies to Participate in Upcoming November Investor Conferences
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in November:
Guggenheim Securities 3rd Annual Healthcare Innovation Conference – November 9, 2026Format: Fireside ChatTime: 8:00 am ETLocation: Boston, MA
2026 LifeSci Growth & Innovation Summit – November 16, 2026Format: 1 on 1 MeetingsLocation: London, UK
A live webcast of the fireside chat will be available on the Events section of the Company's website here.
Replays will also be available on DBV Technologies’ website for 90 days after the event.
About DBV TechnologiesDBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® Patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact Virginie BoucinhaDBV Technologies[email protected]
Media ContactBrett WhelanDBV Technologies[email protected]
Attachment
PDF Version